BLA 761297 · Checkpoint Therapeutics INC
Unloxcyt
Cosibelimab-Ipdl · Injection · Programmed Death Ligand-1 Blocker
NovelCDER novel approval, Dec 13, 2024: To treat cutaneous squamous cell carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Dec 13, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
6
1 Phase 3, 1 recruiting
FAERS reports
7
1 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 21, 2026.
1. INDICATIONS AND USAGE UNLOXCYT ® is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. UNLOXCYT is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
Mechanism: PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production. Cosibelimab-ipdl binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the inhibitory effects of PD-L1 on the anti-tumor immune response. Cosibelimab-ipdl has also been shown to induce...
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 21, 2025 Supplement 1 · Efficacy LetterLabel
- Dec 13, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- UNLOXCYT · COSIBELIMAB-IPDL 300MG/5ML(60MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cosibelimab" as an intervention, any sponsor and status, largest first.
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruiting
Checkpoint Therapeutics, Inc.Industry
NCT03212404 · 272 participants · Start Sep 20, 2017 · Primary completion Nov 18, 2021
Drug: CK-301 (cosibelimab) · For: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell and 10 more
Sites: Wollongong, Australia; Benowa, Australia; Buderim, Australia · 48 sites in all
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07426484 · 80 participants (planned) · Start Apr 23, 2026 · Primary completion Dec 15, 2030
Drug: Cosibelimab; Prednisone and 2 more · For: Cutaneous Squamous Cell Carcinoma; Skin Cancer
Sites: Boston, Massachusetts · 2 sites in all
- Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLCPivotal-lookingTerminated
Checkpoint Therapeutics, Inc.Industry
NCT04786964 · 25 participants · Start Dec 8, 2021 · Primary completion Dec 30, 2023
Drug: Cosibelimab; Cisplatin and 3 more · For: Metastatic Non-squamous Non Small Cell Lung Cancer
Sites: Vitória, Brazil; Tbilisi, Georgia; Kota Bharu, Malaysia · 22 sites in all
- Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruiting
Arsen OsipovAcademic, hospital or other
NCT06981806 · 24 participants (planned) · Start Jan 2026 · Primary completion Feb 2027
Drug: Balixafortide; Balixafortide and 2 more · For: Metastatic Pancreatic Ductal Adenocarcinoma
Sites: Los Angeles, California
TG Therapeutics, Inc.Industry
NCT03778073 · 18 participants · Start Apr 17, 2019 · Primary completion May 3, 2022
Drug: Cosibelimab; Cosibelimab + Ublituximab + Bendamustine combination and 1 more · For: B-cell Non Hodgkin Lymphoma; Richter's Transformation
Sites: Huntsville, Alabama; Tucson, Arizona; Fayetteville, Arkansas · 9 sites in all
- Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary SyndromeNot yet recruiting
City of Hope Medical CenterAcademic, hospital or other
NCT07926893 · 14 participants (planned) · Start May 16, 2027 · Primary completion May 16, 2028
Drug: Cosibelimab; Lenalidomide · For: Recurrent Mycosis Fungoides; Recurrent Sezary Syndrome; Recurrent Transformed Mycosis Fungoides and 7 more
Sites: Duarte, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- alopecia1
- death1
- fatigue1
- illness1
- liver disorder1
- product storage error1
- product storage issue1
- pruritus1
- swelling face1
- therapy cessation1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ࣙ2 years.
Ruiz ES, Muñoz-Couselo E, Montaudié H, et al. · J Am Acad Dermatol 2026 · Clinical Trial, Multicenter Study
Sponsor: Checkpoint Therapeutics INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.